Semaglutide vs Tirzepatide:
The Definitive Comparison
SURMOUNT-5 (NEJM 2025) settled the debate: Tirzepatide delivered 47% greater weight loss than Semaglutide head-to-head. Here's the full data from both trial programs.
All content is for educational and research purposes only. Peptides discussed are research compounds not approved by the FDA for human use. Nothing on this page constitutes medical advice.
SURMOUNT-5: The Verdict (NEJM 2025)
751 participants · 72 weeks · Maximum tolerated doses · 1:1 randomized
-20.2%
Tirzepatide
10–15mg
-13.7%
Semaglutide
1.7–2.4mg
47%
Greater Weight Loss
Tirzepatide advantage
50.3 lbs
Tirzepatide Avg Loss
vs 33.1 lbs sema
Mechanism Comparison
Semaglutide (Wegovy / Ozempic)
GLP-1 Receptor Only
- 94% structural homology to human GLP-1
- Half-life ~7 days (165 hours)
- 89% subcutaneous bioavailability
- Available in oral form (Rybelsus)
- SELECT trial: 20% MACE reduction (n=17,604)
Tirzepatide (Zepbound / Mounjaro)
Dual GIP + GLP-1 Receptor
- GIP receptor affinity equals native GIP
- Half-life ~5 days (120 hours)
- Synergistic GIP + GLP-1 co-activation
- 47% greater weight loss vs semaglutide (SURMOUNT-5)
- Lower GI discontinuation: 2.7% vs 5.6%
STEP Trial Program
| Trial | n | Duration | Weight Loss |
|---|---|---|---|
| STEP 1 | 1,961 | 68 wks | -14.9% |
| STEP 2 (T2D) | 1,210 | 68 wks | -9.6% |
| STEP 3 (+ behavioral) | 611 | 68 wks | -16.0% |
| STEP 5 (2 year) | 304 | 104 wks | -15.2% |
Consider Retatrutide — -28.7% Weight Loss
The triple-agonist outperforms both. Retatrutide adds glucagon receptor activation on top of GLP-1 + GIP.
SURMOUNT Trial Program
| Trial | n | Duration | Best Result |
|---|---|---|---|
| SURMOUNT-1 | 2,539 | 72 wks | -22.5% (15mg) |
| SURMOUNT-2 (T2D) | 938 | 72 wks | -15.7% (15mg) |
| SURMOUNT-4 (withdrawal) | 670 | 88 wks | +14% regain off drug |
| SURMOUNT-5 (vs sema) | 751 | 72 wks | -20.2% vs -13.7% |
SURMOUNT-1 highlight: at 15mg, 39.7% of participants lost ≥25% body weight — a threshold previously only achievable through bariatric surgery.
Cardiovascular Outcomes
Semaglutide — SELECT Trial
17,604 participants across 41 countries
Obese adults with established CVD, without diabetes
Result: 20% reduction in MACE (HR 0.80, p<0.001)
First GLP-1 CV benefit demonstrated in a non-diabetic obese population
Tirzepatide — CV Data
No dedicated MACE-endpoint trial completed as of March 2026
SURMOUNT trials show favorable: ↓BP, ↓lipids, ↓hsCRP
SURPASS-2: superior A1C reduction vs semaglutide 1mg in T2D
For CV endpoint research: semaglutide has stronger evidence base
Which Should You Research?
Choose Semaglutide when:
- Studying pure GLP-1 receptor pharmacology
- Cardiovascular endpoint research (SELECT trial data)
- Oral formulation studies (Rybelsus)
- Long-duration efficacy (104-week STEP 5 data)
- Lower dose protocols / budget constraints
Choose Tirzepatide when:
- Maximizing weight loss magnitude (-22.5% vs -14.9%)
- Dual GIP/GLP-1 co-agonism research
- Tolerability-focused research (2.7% vs 5.6% discontinuation)
- Glycemic control studies (superior HbA1c vs sema 1mg)
- Higher-dose protocols ($3.83/mg vs $9.33/mg at best price)
Research Pricing at Clav Tides
Frequently Asked Questions
Is tirzepatide more effective than semaglutide?
Yes, based on SURMOUNT-5 (NEJM 2025, n=751, 72 weeks). Tirzepatide produced 47% greater weight loss (-20.2% vs -13.7%). Tirzepatide's GIP + GLP-1 dual agonism produces synergistic metabolic effects exceeding selective GLP-1 agonism.
Does semaglutide have cardiovascular benefits tirzepatide lacks?
Yes. SELECT trial (n=17,604, 41 countries) showed 20% MACE reduction with semaglutide in obese adults without diabetes (HR 0.80, p<0.001). No equivalent tirzepatide CVOT has been completed as of March 2026.
Which has fewer side effects?
In SURMOUNT-5 head-to-head: tirzepatide had 2.7% GI-related discontinuation vs semaglutide's 5.6%. Despite greater efficacy, tirzepatide was better tolerated — possibly because GIP receptor activation modulates GI signaling differently.
What happens when you stop taking them?
Both show significant regain. STEP 4: +6.9% regain (vs -7.9% additional loss for continuers). SURMOUNT-4: +14.0% regain (vs -5.5% additional for continuers). Only 16.6% who stopped tirzepatide maintained ≥80% of lost weight vs 89.5% who continued.
What about retatrutide — is it better than both?
Yes in terms of weight loss. Retatrutide (triple GLP-1/GIP/Glucagon agonist) delivered -28.7% in TRIUMPH-4 Phase 3, vs -22.5% tirzepatide and -14.9% semaglutide. However, it has higher GI side effects (18.2% discontinuation) and is not yet FDA-approved.
Shop Both
Research-grade Semaglutide and Tirzepatide — >98% purity, COA documentation.
Related Research Guides
- Weight Loss
Retatrutide: The Triple-Agonist That Surpasses Both
-28.7% Phase 3 weight loss. The glucagon receptor adds what GIP/GLP-1 alone cannot.
- Peptide Stacking
Complete Guide to Peptide Stacking
Combining GLP-1 class peptides with other research compounds — evidence grades and FDA status.
- Protocol Research
Clavicular Retatrutide Protocol Breakdown
The retatrutide-centered research protocol with full compound rationale and sourcing.
- Education
How Peptides Work: Beginner's Guide
GLP-1 receptor biology, signal transduction, and the incretin taxonomy explained.